Performance Improvement

A&M professionals seek to deliver both sustained growth in revenue and improvements in earnings. Working alongside boards and management of hospitals and health systems, academic medical centers, skilled nursing facilities, acute care facilities, surgery centers, community hospitals, pharmaceutical companies and HMOs, we have realized dramatic and durable improvements in enterprise-wide financial results through deployment of a wide range of capabilities, including pricing strategy, managed care negotiations, cost management and revenue cycle optimization.

Rely on us for help with:

Financial Performance Improvement
Operational Performance Improvement
Clinical Effectiveness
Quality
Information Technology Assessment and Integration
Revenue Cycle Management
Supply Chain
Regulatory and Compliance

Business Office Efficiency
Managed Care Strategy
Risk Advisory
Budgeting / Financial Planning
Capital Programs
Labor Productivity
Clinical Documentation and Coding Reviews

Thought Leadership

Disruption in the ACA Market – Implications and Strategic Responses

June 11, 2025

In a recent article, A&M Healthcare Industry Group experts explore key policy changes, market dynamics, stakeholder implications and strategic actions for navigating the evolving landscape surrounding the Affordable Care Act marketplace.

Thought Leadership

The Effect of Trump’s Tariffs on the European Pharmaceutical and Biopharmaceutical Industry

June 9, 2025

As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could be felt across the global healthcare landscape.

Press Releases

FORMER FEDERAL HEALTH MINISTER PROFESSOR GREG HUNT JOINS ALVAREZ & MARSAL AUSTRALIA

May 27, 2025

Alvarez & Marsal appoints The Honourable Greg Hunt as a Senior Advisor bolstering its Healthcare and Public Sector advisories in support of maximizing sustainable value for clients.

Thought Leadership

Contract Research Organisations M&A Market

March 28, 2025

Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).